Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database"

MeSH terms

• Adverse Drug Reaction Reporting Systems
• Biosimilar Pharmaceuticals* / adverse effects
• Databases, Factual
• Humans
• Neoplasms* / drug therapy
• United States
• United States Food and Drug Administration